Answers are grounded in this paper and cite their sources.
The application of immunohistochemical techniques developed in the last decades has led to substantial progress in the pathology of lymphatic tissues, contributing to a better understanding and characterization of inflammatory and neoplastic processes. Stein and coworkers (1,2) contributed the production of the monoclonal antibody Ki-1 (CD-3O) to this progress. Their work was presented initially as a marker reacting selectively with Hodgkin's and Reed-Steinberg cells of Hodgkin's disease and with a small population of large cells preferentially localized around B cell follicles in stimulated lymph nodes. Further studies performed in the following years demonstrated that the Ki-1 antigen is not expressed only by a particular population of mature or precursor B or T lymphocytes, but that it may be induced in either cell types by stimulation with certain agents including bacteria, such as StaphylococcuS aureus, viruses of type HLTV I and II, and Epstein-Barr virus (3). The application of CD-3O to lymphatic infiltrates of the skin resulted in recognition of a series of malignant lymphomas characterized by a population of large cells that reacted strongly with this antibody. Some of these lymphomas have been previously believed to represent malignant histiocytic tumors. The new findings resulted in a classification of CD-3O–cutaneous lymphomas (4,5). Many papers have been written about CD-30–positive lymphomas of the skin, but very little is known about inflammatory diseases of the skin with immunoexpression of the antibody CD-3O. In fact, identification of CD-3O–positive cells in cutaneous lymphocytic infiltrates has been used as a strong argument for diagnosing malignancy. In this context, CD-3O has been considered to be a reliable tool in the differential diagnosis between insect bites and lymphomatoid papulosis (6). However, in the skin, as previously demonstrated in lymph nodes, there is increasing evidence that a number of noxae can stimulate the activation of lymphocytes giving rise to an immunoresponse characterized by proliferation of a reactive population of CD-3O–positive cells apparently indistinguishable from those observed in certain malignant lymphomas (7–9). Recently, McCalmont and LeBoit reported on the case of an elderly female with a pruritic papular eruption involving the trunk and the extremities that was suspected to represent lymphomatoid papulosis clinically and histopathologically. A significant number of CD-3O–positive cells was found. The presence of a mite in the overlying cornified layer confirmed that the correct diagnosis was scabies and not lymphoma (10). We recently had the opportunity of studying one case that reinforces the message of McCalmont and LeBoit; namely, the presence of numerous CD-30–positive cells in inflammatory infiltrates of the skin in the absence of malignant lymphoma. In our case, a basal-cell carcinoma was removed from the back of a 70 year-old male. Microscopically, the tumor was surrounded by a dense lympho-plasmacellular infiltrate containing numerous large cells with prominent nuclei and abundant pale eosinophilic cytoplasm (Fig. 1). They were distributed in small groups or as solitary units (Fig. 2). Immunohistochernically, large cells were positive for UCHL-1 and CD-3O (Fig. 3), whereas L26 was negative. Plasma cells were polyclonal in nature as demonstrated by immunoexpression of both light chains of immunoglobulins kappa and lambda. This case provides evidence that activated CD-3O–positive lymphocytes may also be found in the inflammatory response around basal cell carcinoma.FIG. 1.: Basal cell carcinoma surrounded by a prominent lympho-plasmacellular infiltrate.FIG. 2.: Numerous large lymphocytes in association with plasma cells around basal cell carcinoma.FIG. 3.: Large lymphocytes around basal cell carcinoma showing prominent immunoexpression for CD-30.On the basis of these findings it is obvious that the presence of CD-3O–positive cells in a lymphomatoid infiltrate of the skin does not qualify it for being considered malignant. Other parameters need to be analyzed before the diagnosis of malignant lymphoma. In regard to cutaneous infiltrates of B lymphocytes, demonstration of monotypic light chain expression or lack of detectable immunoglobulins are the most reliable criteria for diagnosing malignancy. Differential diagnosis between benign and malignant becomes more difficult in those cases in which the cutaneous infiltrate is composed mainly of T lymphocytes. The advent of genetic studies performed on lymphatic infitrates of the skin brought new relevant information on the molecular structure of these cells but, at the same time, considerable problems in the interpretation of results. In fact, the value of T-cell receptor rearrangement analysis in the differential diagnosis between benign and malignant lesions remains to be established. The existence of cases of clonal rearrangement of T-cell receptor genes in cutaneous T-cell pseudolymphomas implicates that such technique can not be used as a gold standard in the differential diagnosis between lymphomas and pseudolymphomas (11). It is my belief that, although differentiation between benign and malignant is often possible using a combination of clinical, histopathologic, immunophenotypic, and even cytogenetic findings, there is no single reliable criterium that allows distinction between inflammatory and neoplastic in lympho-proliferative skin disorders. Large, atypical lymphocytes expressing CD-3O may be part of an inflammatory response and do not qualify alone for the diagnosis of malignant lymphoma. Carlos Diaz-Cascajo M.D.
No takes yet. Share an insight, caveat, or question.
Carlos Díaz‐Cascajo (2001) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: